HC Advisors’s Pliant Therapeutics PLRX Stock Holding History

HC Advisors’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,493	Closed	-$216K	–	91
2021 Q1	$216K	Buy	+5,493	New	+$178K	0.14%	74

Other funds holding PLRX

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

HC Advisors's PLRX Position: Q2 2021 in Review

HC Advisors sold out of Pliant Therapeutics (PLRX) in Q2 2021, closing a stake of 5,493 shares — an estimated $216K sold.

HC Advisors first reported a position in PLRX in Q1 2021 and held it in 1 quarter. The position peaked at $216K in Q1 2021. 81 funds tracked by Wall St. Rank hold PLRX as of Q2 2021.

HC Advisors reported no remaining Pliant Therapeutics position as of Q2 2021 after selling out during the quarter.
HC Advisors sold 5,493 Pliant Therapeutics shares in Q2 2021, an estimated $216K.
HC Advisors first reported a position in Pliant Therapeutics in Q1 2021 and held it in 1 quarter.
HC Advisors's Pliant Therapeutics position peaked at $216K in Q1 2021.
81 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2021.

Based on HC Advisors's 13F filing for Q2 2021, filed 9 Aug 2021.